Parkinson D
J Neurosurg. 1983 Dec;59(6):990-3. doi: 10.3171/jns.1983.59.6.0990.
The authors report a 12-year follow-up review of 33 patients treated with chymopapain (Discase) injection for intervertebral disc disease. This carefully controlled series of patients was treated under local anesthesia in the prone position. Only the single offending disc that correlated with the myelographic and clinical pathology (without the use of discography) was injected with Discase. Anaphylaxis is treated instantly at the first sign of disturbance, and no patients suffered shock. The percentage of patients who were completely cured or improved continues at about 70%. Aside from sensitivity, complications attributable to proper use of the enzyme remain at zero. Follow-up review of those patients over 10 years would indicate that there is no risk of delayed organ toxicity, no risk of carcinogenesis, and no apparent risk of first-generation teratogenesis.
作者报告了对33例接受木瓜凝乳蛋白酶（椎间盘酶）注射治疗椎间盘疾病患者的12年随访回顾。这组经过精心对照的患者在局部麻醉下俯卧位接受治疗。仅对与脊髓造影和临床病理相关的单个病变椎间盘（未使用椎间盘造影）注射椎间盘酶。一旦出现过敏反应迹象立即进行治疗，没有患者发生休克。完全治愈或病情改善的患者比例持续保持在约70%。除了过敏反应外，正确使用该酶引起的并发症仍为零。对这些患者超过10年的随访回顾表明，不存在延迟性器官毒性风险、致癌风险以及第一代致畸的明显风险。
